Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
PEX19 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P40855 |
|---|---|
| Clone Names | 100517307 |
| Gene ID | 5824 |
|---|---|
| Other Names | Peroxisomal biogenesis factor 19, 33 kDa housekeeping protein, Peroxin-19, Peroxisomal farnesylated protein, PEX19, HK33, PXF |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | PEX19 (HGNC:9713) |
|---|---|
| Synonyms | HK33, PXF |
| Function | Necessary for early peroxisomal biogenesis. Acts both as a cytosolic chaperone and as an import receptor for peroxisomal membrane proteins (PMPs). Binds and stabilizes newly synthesized PMPs in the cytoplasm by interacting with their hydrophobic membrane-spanning domains, and targets them to the peroxisome membrane by binding to the integral membrane protein PEX3. Excludes CDKN2A from the nucleus and prevents its interaction with MDM2, which results in active degradation of TP53. |
| Cellular Location | Cytoplasm. Peroxisome membrane; Lipid-anchor; Cytoplasmic side. Note=Mainly cytoplasmic. Some fraction membrane-associated to the outer surface of peroxisomes. |
| Tissue Location | Ubiquitously expressed. Isoform 1 is strongly predominant in all tissues except in utero where isoform 2 is the main form. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene is necessary for early peroxisomal biogenesis.It acts both as a cytosolic chaperone and as an import receptor forperoxisomal membrane proteins (PMPs). Peroxins (PEXs) are proteinsthat are essential for the assembly of functional peroxisomes. Theperoxisome biogenesis disorders (PBDs) are a group of geneticallyheterogeneous autosomal recessive, lethal diseases characterized bymultiple defects in peroxisome function. These disorders have atleast 14 complementation groups, with more than one phenotype beingobserved for some complementation groups. Although the clinicalfeatures of PBD patients vary, cells from all PBD patients exhibita defect in the import of one or more classes of peroxisomal matrixproteins into the organelle. Defects in this gene are a cause ofZellweger syndrome (ZWS), as well as peroxisome biogenesis disordercomplementation group 14 (PBD-CG14), which is also known asPBD-CGJ. Alternative splicing results in multiple transcriptvariants.
References
Mohamed, S., et al. Am. J. Med. Genet. A 152A (9), 2318-2321 (2010) :Schmidt, F., et al. J. Biol. Chem. 285(33):25410-25417(2010)Schueller, N., et al. EMBO J. 29(15):2491-2500(2010)Liu, Y., et al. J Psychiatr Res (2010) In press :Matsuzono, Y., et al. J. Biol. Chem. 281(1):36-42(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
